[Featured Stock] Humasis Soars Over 19% on US Approval of COVID-19 Antigen Test Kit

[Asia Economy Reporter Park Jihwan] Humasis is experiencing a surge of over 19% following the news of the Emergency Use Authorization (EUA) granted by the U.S. Food and Drug Administration (FDA) for the COVID-19 rapid diagnostic kit jointly developed with Celltrion.

According to the Korea Exchange on the 19th, as of 10:50 AM, Humasis was trading at 14,350 KRW, up 2,300 KRW (19.09%) from the previous trading day. Earlier in the session, the stock price rose as much as 27.39%, approaching the upper price limit.

On the same day, Humasis announced that the COVID-19 rapid antigen diagnostic kit "Diatrust," co-developed with Celltrion, had received Emergency Use Authorization from the U.S. FDA.